ATE519784T1 - An den humanen igg-fc-rezeptor iib (fcgammariib) bindende substanz - Google Patents

An den humanen igg-fc-rezeptor iib (fcgammariib) bindende substanz

Info

Publication number
ATE519784T1
ATE519784T1 AT04798098T AT04798098T ATE519784T1 AT E519784 T1 ATE519784 T1 AT E519784T1 AT 04798098 T AT04798098 T AT 04798098T AT 04798098 T AT04798098 T AT 04798098T AT E519784 T1 ATE519784 T1 AT E519784T1
Authority
AT
Austria
Prior art keywords
fcgammariib
human igg
substance binding
receptor iib
relates
Prior art date
Application number
AT04798098T
Other languages
English (en)
Inventor
Robert Huber
Peter Sondermann
Uwe Jacob
Kerstin Wendt
Cabrele Chiara
Luis Moroder
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE519784T1 publication Critical patent/ATE519784T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
AT04798098T 2003-11-26 2004-11-26 An den humanen igg-fc-rezeptor iib (fcgammariib) bindende substanz ATE519784T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03027000 2003-11-26
PCT/EP2004/013450 WO2005051999A2 (en) 2003-11-26 2004-11-26 Substance binding human igg fc receptor iib

Publications (1)

Publication Number Publication Date
ATE519784T1 true ATE519784T1 (de) 2011-08-15

Family

ID=34626375

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04798098T ATE519784T1 (de) 2003-11-26 2004-11-26 An den humanen igg-fc-rezeptor iib (fcgammariib) bindende substanz

Country Status (11)

Country Link
US (2) US8853363B2 (de)
EP (1) EP1709073B1 (de)
JP (1) JP5652987B2 (de)
AT (1) ATE519784T1 (de)
AU (1) AU2004293184B2 (de)
CA (1) CA2547126C (de)
ES (1) ES2371468T3 (de)
NZ (1) NZ547629A (de)
PL (1) PL1709073T3 (de)
PT (1) PT1709073E (de)
WO (1) WO2005051999A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1709073B1 (de) * 2003-11-26 2011-08-10 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. An den humanen igg-fc-rezeptor iib (fcgammariib) bindende substanz
WO2006002930A2 (en) * 2004-06-30 2006-01-12 Friedrich-Alexander- Universitaet Erlangen- Nuernberg FcϜRIIa POLYMORPHISM AND ITS USE IN DIAGNOSIS
EP1870422A1 (de) * 2006-06-20 2007-12-26 SuppreMol GmbH Mittel zur Behandlung von Erkrankungen, die durch eine übermässige Immunreaktion gekennzeichnet sind
EP2626371A1 (de) 2007-07-31 2013-08-14 MedImmune, LLC Multispezifische Epitopbindeproteine und ihre Verwendungen
KR101397554B1 (ko) 2007-11-09 2014-05-21 재단법인서울대학교산학협력재단 치매(알츠하이머 병)의 진단, 예방, 치료제 및 이들의스크리닝 방법
WO2009083009A2 (en) 2008-01-03 2009-07-09 Genmab A/S Monoclonal antibodies against cd32b
GB201013989D0 (en) 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
EP2669295A1 (de) 2012-05-29 2013-12-04 Universitätsklinikum Regensburg Diagnoseverfahren zur Bestimmung des Vorhandenseins und der Menge von menschlichem Interleukin-3 in einer Probe unter Verwendung neuer IL-3-Antikörper
EP2669294A1 (de) 2012-05-29 2013-12-04 Universitätsklinikum Regensburg Neue IL-3-Antikörper und deren Verwendung bei der Diagnose und Behandlung von Krankheiten oder Fehlfunktionen im Zusammenhang mit erhöhten IL-3-Werten
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US10669324B2 (en) * 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2837637A1 (de) * 2013-08-16 2015-02-18 SuppreMol GmbH Neuartiger FcyRIIB IgG-Antikörper
CA2957850A1 (en) * 2014-08-13 2016-02-18 Suppremol Gmbh Antibodies comprising binding domains to fc.epsilon. receptor (fc.epsilon.r) and fc gamma receptor iib (fc.gamma.riib)
WO2017081218A2 (en) 2015-11-11 2017-05-18 Universitätsklinikum Regensburg Anti-human il-3 antibodies, their use in treatment of a disease or malfunction associated with elevated expression or levels of il-3, and their use in a method to detect human il-3
CN111778256B (zh) * 2020-04-20 2022-03-25 广东省微生物研究所（广东省微生物分析检测中心） CircRNA PVT1及其肽段PVT1-104aa在抗衰老方面的应用
WO2022192532A1 (en) * 2021-03-12 2022-09-15 The Rockefeller University Glycoform specific nanobodies and methods of use
WO2023019200A1 (en) 2021-08-11 2023-02-16 Viela Bio, Inc. Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease
EP4608515A1 (de) 2022-10-25 2025-09-03 Seismic Therapeutic, Inc. Variante igg-fc-polypeptide und verwendungen davon

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
US5612030A (en) * 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
AU5504999A (en) * 1998-07-20 2000-02-14 Frenken, Leon Gerardus Joseph Production of proteins
AU769489B2 (en) * 1998-09-11 2004-01-29 Ilexus Pty Limited Fc receptor modulators and uses thereof
EP1006183A1 (de) * 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Rekombinante, lösliche Fc-Rezeptoren
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7416726B2 (en) * 2000-04-13 2008-08-26 The Rockefeller University Enhancement of antibody-mediated immune responses
EP1298205A4 (de) 2000-07-03 2004-06-16 Mochida Pharm Co Ltd Neuartige lipase
US20020111969A1 (en) 2000-09-28 2002-08-15 Halstead Robert H. System and method for processing graphical objects for layout using an elastic difference operation
AU2001278773A1 (en) * 2000-10-11 2002-04-22 Mochida Pharmaceutical Co., Ltd. Novel pla1
JP4232423B2 (ja) * 2001-09-28 2009-03-04 第一三共株式会社 新規ユビキチン特異プロテアーゼ
DE10157290A1 (de) * 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
US6911321B2 (en) * 2001-12-19 2005-06-28 Genentech, Inc. Non-human primate Fc receptors and methods of use
TWI265697B (en) 2002-06-06 2006-11-01 Ibm Digital contents distribution system, digital contents distribution method, computer readable recording medium storing the program therein, and server and client therefor
JP4459810B2 (ja) * 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
EP1709073B1 (de) * 2003-11-26 2011-08-10 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. An den humanen igg-fc-rezeptor iib (fcgammariib) bindende substanz

Also Published As

Publication number Publication date
JP5652987B2 (ja) 2015-01-14
US20080014141A1 (en) 2008-01-17
ES2371468T3 (es) 2012-01-03
PL1709073T3 (pl) 2012-01-31
CA2547126C (en) 2014-07-15
US20120269837A1 (en) 2012-10-25
US8853363B2 (en) 2014-10-07
WO2005051999A2 (en) 2005-06-09
PT1709073E (pt) 2011-09-29
AU2004293184B2 (en) 2010-12-16
JP2008502312A (ja) 2008-01-31
NZ547629A (en) 2009-08-28
AU2004293184A1 (en) 2005-06-09
WO2005051999A3 (en) 2005-11-24
EP1709073A2 (de) 2006-10-11
CA2547126A1 (en) 2005-06-09
EP1709073B1 (de) 2011-08-10

Similar Documents

Publication Publication Date Title
ATE519784T1 (de) An den humanen igg-fc-rezeptor iib (fcgammariib) bindende substanz
ECSP21023271A (es) Anticuerpos cd20 con función del efector y afinidad de enlace al receptor fc mejoradas
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
MX2010003380A (es) Proteinas de union a antigeno de factor de crecimiento tipo factor de crecimiento epidermico de union a heparina.
CO5700152A1 (es) Nuevos anticuerpos anti-igf-ir y sus usos
EA200700917A1 (ru) Способ рефолдинга рекомбинантных антител
WO2003034903A3 (en) Psma antibodies and protein multimers
ATE554107T1 (de) Als therapeutika geeignete monovalente antikörperfragmente
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
EP2352523A4 (de) Verbesserte anti-cd19-antikörper
UA115964C2 (uk) Інтерлейкін-13-зв'язувальний білок
TW200732350A (en) Methods for generating monovalent IgG
AR055137A1 (es) Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
DE60139542D1 (de) Methoden zur herstellung humaner monoklonaler antikörper
EA201591355A1 (ru) АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА
WO2008045437A3 (en) Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
WO2007110678A3 (en) Neutralizing antibodies and methods of use thereof
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
IN2009CN03372A (de)
UA87106C2 (uk) БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ РЕЦЕПТОР Nogo
WO2010142551A3 (en) Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
MX2010001237A (es) Nuevos anticuerpos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1709073

Country of ref document: EP